BONDLIDO (Lidocaine) Patent Expiration, LOE Window & CMS Spending

BONDLIDO (Lidocaine) by Medrx Usa: FDA Orange Book core substance LOE 2028-11-10, 0 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMedrx Usa
FDA Application & PathwayN215029 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2028-11-10
Last Listed Patent or Exclusivity Date2028-11-10
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel